Fig. 10From: Matrine combined with cisplatin synergistically inhibited urothelial bladder cancer cells via down-regulating VEGF/PI3K/Akt signaling pathwayThe interactions between the drugs and AKT2(2JDR) in the binding site. Ten random poses of matrine docked into the active site of 2JDR (a). The binding modes of matrine in AKT2: at least one residue involved in the interaction in ten random poses, π–π interaction with Phe163 (b). Ten random poses of cisplatin docked into the same active site of AKT2 (c). The binding modes of cisplatin in AKT2: at least seven residues involved in the interactions in ten random poses, Lys181, Glu236, Asp275, Lys277, Thr292, Asp293, and Leu296 (h-bonds) (d)Back to article page